the patients had a history of cardiovascular disease in CANVAS, 2, 3 indicating that these two SGLT2 inhibitors have shown a favourable cardiovascular effect, predominantly in patients with established cardiovascular disease. In fact, in the subgroup analysis of CANVAS, 2 the significantly improved primary cardiovascular outcome observed in patients with a history of cardiovascular disease was not evident in those without. 2 In this regard, DECLARE-TIMI 58 is of worth because it evaluated the effects of dapagliflozin, another SGLT2 inhibitor, in a 'broad' population of type 2 diabetic patients. 4 1. What was found from the results of DECLARE-TIMI 58?
In DECLARE-TIMI 58, only 40.5% of patients had established atherosclerotic cardiovascular disease. 4 Patients with a creatinine clearance <60%
per minute were excluded. MACE occurred in 8.8% of patients treated with dapagliflozin and in 9.4% of those who received a placebo, a difference that met criteria for non-inferiority but not superiority. However, dapagliflozin did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; P = 0.005), driven totally by the significant reduction in the risk of hospitalization for heart failure. 4 The majority of patients did not have a history of heart failure. Together with the results of EMPA-REG OUTCOME 1 and CANVAS, 2,3 prevention of heart failure, irrespective of the history of established cardiovascular disease, has been closed up as a class effect of SGLT2 inhibitors.
2.
What are the beneficial underlying mechanisms of SGLT2 inhibitors in helping to prevent heart failure?
There have been several experimental reports which investigated the direct effects of SGLT2 inhibitors on cultured cells. [5] [6] [7] Canagliflozin activated AMPK by inhibiting mitochondrial function and increasing cellular AMP levels in HEK-293 cells. 5 It also inhibits interleukin-1b-stimulated cytokine and chemokine secretion in human vascular endothelial cells by AMP-activated protein kinase-dependent and independent mechanisms. 6 In addition, empagliflozin, canagliflozin, and dapagliflozin directly inhibited cardiac Na + /H + exchanger flux and reduced cardiac cytosolic Na + in mouse cardiomyocytes. 7 During in vivo experiments using type 2 diabetic KK-Ay mice, glycaemic control with empagliflozin ameliorated myocardial oxidative stress injury and cardiac fibrosis. 8 More interestingly, even in the absence of elevated blood glucose in a mouse model of pressure overload-induced heart failure, empagliflozin prevented the worsening of cardiac function. 9 These observations suggest that SGLT2
inhibitors may be clinically effective with which to treat heart failure in patients with and without diabetes. Potential mechanisms of SGLT2 inhibitors in preventing heart failure which has been reported so far are described in Figure 1 . cardiovascular surgery, that the fibrotic remodelling of EAT was associated with LA myocardial fibrosis and that LA myocardial fibrosis was positively correlated with proinflammatory and profibrotic cytokines/ chemokines. This includes interleukin-6, monocyte chemoattractant protein-1, tumour necrosis factor-a, and vascular endothelial growth factor in EAT. 10 Cardiac fibrosis is one of the crucial factors in the development of heart failure, particularly in patients with preserved ejection fraction (HFpEF). In this regard, obesity and other chronic inflammatory disorders lead to the accumulation and inflammation of EAT, which may have important implications for the pathogenesis of HFpEF. 11 There is a very fascinating study, focusing on the effects of dapagliflozin on human EAT and preadipocyte. 12 Dapagliflozin increased glucose uptake, reduced the secretion of pro-inflammatory chemokines, and improved the differentiation of EAT cells. 12 In fact, SGLT2 inhibitor reportedly reduced the total amount of EAT in patients with type 2 diabetes. 13 More recently, it was reported in 64 heart failure patients with left ventricular ejection fraction >40% in comparison with 20 controls, who underwent magnetic resonance examination, that the total volume of epicardial fat was significantly higher in heart failure patients compared with the controls. In addition, heart failure patients with atrial fibrillation and/or type Figure 1 Potential mechanisms of SGLT2 inhibitors in preventing heart failure.
Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin 2 diabetes mellitus had more epicardial fat than heart failure patients without these co-morbidities. 14 Taken together, it can be conceivable to say that increased volume of EAT and its quality deterioration in patients with or without type 2 diabetes may be a potential therapeutic target to prevent heart failure by SGLT2 inhibitors. Progression of imaging technology will make it possible to evaluate the quality of EAT. In the near future, imaging-identified high-risk subjects, that is, obese subjects with the large volume of deteriorated EAT, could be candidates for early administration of SGLT2 inhibitors, to prevent heart failure. On the other hand, chronic activation of the sympathetic nervous system has been identified in patients with heart failure, and was associated with a poor prognosis. 15 In spite of insufficient evidence, it can be hypothesised that SGLT2 takes part in the activation of the sympathetic nervous system and that inhibition of SGLT2 may have a cardiovascular protective effect, by reducing renal afferent nervous activity and suppressing central reflex mechanisms. 15 What implications does DECLARE-TIMI 58 have for the basic science community? Pharmacological treatment for HFpEF is one of the major unmet medical needs. The effects of SGLT2 inhibitors on the prevention of heart failure 1-4 make us expect their specific effectiveness on
HFpEF. Although ongoing trials will answer this question clinically, basic research to clarify the corresponding precise mechanisms should be warranted. On the other hand, the robust effects of SGLT2 inhibitors on the prevention of renal outcomes are also noteworthy, 1-4 because pharmacotherapy to ameliorate diabetic nephropathy is another unmet medical need. Basic research focusing on the effects of SGLT2 inhibitors on diabetic nephropathy should be required. Finally, those focusing on the interaction between SGLT2 inhibitors and the autonomic nervous system should also be required.
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